Gilles Salles

Jan 10, 2024 | nature.com | Gilles Salles

Correction to: Leukemia https://doi.org/10.1038/s41375-020-0743-y, published online 14 February 2020In this article, Figure 1 was incorrect. The updated figure can be found below. The original article has been corrected.

Sep 6, 2023 | targetedonc.com | Gilles Salles |Efrat Luttwak

Bispecific antibodies (BsAbs) represent a significant therapeutic advance in the management of follicular lymphoma (FL).1 The safety profile and high response rates of BsAbs suggest a promising and well-tolerated treatment option for patients with FL. The use of BsAbs has the potential to revolutionize the management of FL.

Sep 4, 2023 | nature.com | Sonja I. Berndt |Nicola J. Camp |Zhaoming Wang |Henrik Hjalgrim |Caroline Besson |Lindsay Morton | +26 more

Correction to: Leukemia https://doi.org/10.1038/s41375-022-01711-0, published online 22 October 2022In this article Arjan Diepstra at affiliation Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands was missing from the author list. The original article has been corrected. About this articleBerndt, S.I., Vijai, J., Benavente, Y. et al.

Jun 9, 2023 | onlinelibrary.wiley.com | Alexander P Boardman |Gilles Salles

1 CAR T-CELL THERAPY IN THIRD AND SUBSEQUENT LINES FOR LBCL Second generation CD19-CAR T-cells bearing a crucial costimulatory molecule first demonstrated pre-clinical efficacy in hematologic malignancies in 2003.1 Since then, several of these products have led to impressive response rates and durable remissions in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), including large B cell lymphoma (LBCL).2-18 Axicabtagene ciloleucel (axi-cel; KTE-C19) is an...